With a view to identifying potential opportunities for earlier referral to specialists and (ultimately) earlier diagnosis of IPF, this study aims to:
1. Evaluate patients’ patterns of HRU in the years preceding their IPF diagnosis.
2. Characterise the clinical features of patients at the time of their IPF diagnosis
Luca Richeldi, National Institute for Health Research, Southampton Respiratory Biomedical Research Unit, University of Southampton, Southampton, UK
David Price: Professor of Primary Care Respiratory Medicine, University of Aberdeen, Aberdeen, UK; Owner of Optimum Patient Care Ltd and REG Chairman
Carlo Vancheri: “Regional Centre for Rare Lung Diseases”, Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy
Christopher Ryerson: Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada; Department of Medicine, University of California San Francisco, San Francisco, California, USA.
Ian Glaspole: Department of Allergy, Immunology and Respiratory Medicine, Alfred Hospital, Melbourne, Australia
Ganesh Ragu: Division of Pulmonary & Critical Care Medicine, University of Washington, Washington, USA
Kevin Flaherty: Department of Medicine, Division of Pulmonary and Critical Care Medicine, University of Michigan Medical School, Ann Arbor, MI, USA
Vincent Cottin: National Reference Centre for Rare Pulmonary Diseases, Department of Respiratory Medicine, Claude Bernard Lyon University, Lyon, France
Toby Maher: National Institute for Health Research (NIHR) Clinician Scientist and Physician on the Interstitial Lung Disease Unit, Royal Brompton Hospital
Andrew Wilson: Norwich Medical School, University of East Anglia, Norwich, UK
Alan Kaplan: Family Physician Airways Group of Canada, Richmond Hill, Ontario, Canada
Martin Kolb: Department of Medicine, Pathology & Molecular Medicine, McMaster University, Hamilton, Ontario, Canada
Alison Chisholm: Chief Scientific Officer of REG, Cambridge, UK